Study of the Neurokinin-1 Receptor Antagonist VPD-737 in Subjects with Prurigo Nodularis

Registry ID

EUCTR2013-005024-42

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Menlo Therapeutics, Inc.

Start date

2014-06-11

Completion date

2016-06-08

Last update

2026-08-16

Conditions

• Prurigo nodularis
• Pruritus nodularis

Summary

The primary objectives of this study are to evaluate the efficacy and safety of VPD-737 5-mg tablets and the placebo taken orally once daily for 8 weeks for the treatment of prurigo nodularis (PN).

Locations

• , , Poland
• , , Ireland
• , , Germany

Related clinical trials

• SWITCH project: Definition of treat-to-target criteria for shared decision making between patients and physicians about initiating, continuing or switching systemic treatment for chronic prurigo and chronic pruritus
• Use of the WHO-5 in chronic pruritus and chronic prurigo and development of a skin well-being questionnaire
• Definition of Severity and Descriptors of Chronic Prurigo – Harmonization of European Prurigo Documentation
• Acceptance and benefit of pruritus measurement in dermatological routine care
• European Prurigo Project (EPP) of the EADV Task Force Pruritus

View on source registry